Skip to main content
. 2022 Jan 20;17(1):e0261775. doi: 10.1371/journal.pone.0261775

Fig 6. CVL activity against HIV-1 and HPV16 PsV.

Fig 6

(A) TMZ-bl cells were incubated with cell-free HIV-1ADA-M and different dilutions of CVLs collected at BL, 4 or 8h post single GRFT/CG gel administration and 24h after 14 day repeated gel administration (randomized study). The EC50 and 95% CI were calculated using a curve-fitting analysis with GraphPad Prism. The Spearman correlation analysis demonstrated that the higher the concentration of GRFT in CVL, the more potent the antiviral activity against HIV-1ADA-M in the MAGI assay. (B) HeLa cells were incubated with HPV16 PsV and different dilutions of CVLs collected at BL, 4 or 8h post single PC-6500 gel administration and 24h post last gel administration (randomized study). The EC50 and 95% CI were calculated using a curve-fitting analysis with GraphPad Prism. (C) Polarized cervical explant cultures were challenged with 500 TCID50 HIV-1BaL in the presence of CVLs collected at BL; 4, 6 or 8h post single and 24h after 14 day repeated gel administration (randomized study) applied on the epithelial surface for 2h (two explants per condition). Tissues were washed and cultured for 14d. Infection was monitored by HIV gag qRT-PCR using supernatants collected every 3-4d. 3TC (4μl of 500μM stock applied on the epithelium) control was included where feasible. The Spearman correlation analysis demonstrated that the higher the concentration of GRFT in CVLs, the more potent the antiviral activity against HIV-1BaL.